Publications by authors named "Mark Freedman"

Claim this Profile
L
Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.
Rebecca I Spain, M Mateo Paz Soldán, Mark S Freedman, Pavle Repovic, Andrew J Solomon

Neurology· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.
Tjalf Ziemssen, Mark S Freedman, Amit Bar-Or, Xavier Montalban, Charlotte E Teunissen

Mult Scler· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis.
Stephen L Hauser, Mark S Freedman, Jin Nakahara, David Paling, Jérôme de Seze

Mult Scler Relat Disord· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.
Ahmed Abdelhak, Franziska Bachhuber, Kiarra Ning, Pascal Benkert, W John Boscardin, Mark S Freedman

J Neurol Neurosurg Psychiatry· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.
Ludwig Kappos, Michel Burcklen, Daniele D'Ambrosio, Robert J Fox, Mark S Freedman

Mult Scler Relat Disord· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis.
Florian Deisenhammer, Harald Hegen, Georgina Arrambide, Brenda L Banwell, Tim Coetzee, Mark S Freedman

EBioMedicine· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
Xavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, Georgina Arrambide, Marcello Moccia, Mark S Freedman

Lancet Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis.
Laura Ghezzi, Peter Kosa, Mark Greenwood, Enrique Alvarez, C L Freedman, Mark S Freedman

Ann Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay.
Ronald A Booth, Daniel Beriault, Raphael Schneider, Pascal Benkert, Eline A J Willemse, Mark S Freedman

Clin Chim Acta· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.
Bruce A C Cree, Mark S Freedman, Michael Gold, Kimberly Pfleeger, Brittany Schwefel

Ann Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of laboratory practices for CSF oligoclonal banding and associated tests.
Victoria Higgins, Yu Chen, Mark S Freedman, Karina Rodriguez-Capote, Daniel R Beriault

Crit Rev Clin Lab Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
Marianna Cortese, Xiaojing Peng, Gilles Edan, Mark S Freedman, Hans-Peter Hartung

Neurology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins

Brain· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions.
Gauruv Bose, Simon D X Thebault, Giulia Fadda, John A Brooks, Mark S Freedman

Neurotherapeutics· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The utility of serum neurofilament light chain in MOGAD: Current insights and future directions.
Mark Labib, Simon Thebault, Ronald A Booth, John Brooks, Carolina Rush, Mark S Freedman

Mult Scler Relat Disord· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus Recommendations.
Mark S Freedman, Fraser Clift, Virginia Devonshire, François Émond, Catherine Larochelle

Can J Neurol Sci· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of vision-related quality of life in NMOSD and MOGAD.
Adnan A Gassan, Andrea Konig, Rosane Nisenbaum, Mark S Freedman, Liesly Lee

Mult Scler Relat Disord· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.
Mark S Freedman, Ahmed Abdelhak, Mohit K Bhutani, Jason Freeman, Sharmilee Gnanapavan

J Neurol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.
Paolo A Muraro, Alice Mariottini, Raffaella Greco, Joachim Burman, Ellen Iacobaeus, Mark S Freedman

Nat Rev Neurol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman

Mult Scler· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical Activity Together for MS: Quality Participation Experiences of People With Multiple Sclerosis and Their Caregivers in a Dyadic Physical Activity Intervention.
Afolasade Fakolade, Miles Lambert, Mariah Keeling, Katherine Cardwell, Emily Broitman, Mark Freedman

Int J MS Care· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
Hans-Peter Hartung, Ralph H B Benedict, Thomas Berger, Robert A Bermel, Bruno Brochet, Mark S Freedman

Neurology· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis.
Simon Thebault, Seyed-Mohammad Fereshtehnejad, Hailey P Bergman, Gautier Breville, Mohammad Abdoli, Mark S Freedman

Sci Rep· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there a prodrome to NMOSD? An investigation of neurologic symptoms preceding the first NMOSD attack.
Sydney Lee, Ruth Ann Marrie, Giulia Fadda, Mark S Freedman, Liesly Lee

Mult Scler· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI graph parameters are longitudinal markers of neuronal integrity in multiple sclerosis.
Milad Hamwi, Simon Thebault, Gerd Melkus, Angela M Auriat, Alex Pham, Mark S Freedman

Mult Scler Relat Disord· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis